Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coltene Holding AGXSWX:CLTN -0.38%69 EV-to-EBITDA is 12.83 as of Jul. 21, 2026, which is 2% below its 10-year median of 13.07. GuruFocus rates XSWX:CLTN with a GF Score™ of 69/100 and a GF Value™ of CHF55.12 (Fairly Valued). The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Coltene Holding AG ranks better than 56.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Coltene Holding AG's enterprise value is CHF335.9 Mil.
Coltene Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF26.2 Mil. Therefore, Coltene Holding AG's EV-to-EBITDA for today is 12.83.
The historical rank and industry rank for Coltene Holding AG's EV-to-EBITDA or its related term are showing as below:
XSWX:CLTN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.18 Med: 13.07 Max: 27.24
Current: 12.83
During the past 13 years, the highest EV-to-EBITDA of Coltene Holding AG was 27.24. The lowest was 8.18. And the median was 13.07.
XSWX:CLTN's EV-to-EBITDA is ranked better than 56.86% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs XSWX:CLTN: 12.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Coltene Holding AG (XSWX:CLTN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Coltene Holding AG's PE Ratio (TTM) for today is calculated as:
Coltene Holding AG's share price for today is CHF51.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Coltene Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF2.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Coltene Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CLTN vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Coltene Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coltene Holding AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coltene Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Coltene Holding AG's EV-to-EBITDA falls into.
Coltene Holding AG's current Enterprise Value is CHF335.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Coltene Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF26.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coltene Holding AG (XSWX:CLTN) has a EV-to-EBITDA of 12.83 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coltene Holding AG. This is near median its historical median of 13.07. Over the past decade, Coltene Holding AG's EV-to-EBITDA has ranged from 8.18 to 27.24. According to the industry distribution chart, Coltene Holding AG ranks #220 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 43.1%.
Is Coltene Holding AG's EV-to-EBITDA too high?
Coltene Holding AG's current EV-to-EBITDA of 12.83 is near median its 10-year median of 13.07. Over the past 10 years, this metric has ranged from a low of 8.18 to a high of 27.24. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.16. Coltene Holding AG's value of 12.83 is 9.4% below this industry median. Based on the distribution chart, Coltene Holding AG ranks #220 out of 510 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coltene Holding AG has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Coltene Holding AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coltene Holding AG ranks #220 out of 510 companies for EV-to-EBITDA. This puts Coltene Holding AG in the upper half of its industry. The industry median EV-to-EBITDA is 14.16. Coltene Holding AG's value of 12.83 is 9.4% below this benchmark. Historically, Coltene Holding AG's own EV-to-EBITDA has ranged from 8.18 to 27.24 over the past decade. While the company's 10-year median is 13.07 vs. the industry median of 14.16, Coltene Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coltene Holding AG's current EV-to-EBITDA of 12.83 is 9.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coltene Holding AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coltene Holding AG's current EV-to-EBITDA is 12.83, which is near median its own 10-year median of 13.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coltene Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Coltene Holding AG (XSWX:CLTN) is currently considered Fairly Valued. The stock's GF Value™ is CHF55.12, compared to a current price of CHF51.80 — trading 6% below its estimated fair value. The current EV-to-EBITDA is 12.83, which is near median its 10-year median of 13.07 and 9.4% below the Medical Devices & Instruments industry median of 14.16. Coltene Holding AG's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Coltene Holding AG (XSWX:CLTN), the current EV-to-EBITDA is 12.83 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coltene Holding AG (XSWX:CLTN) Overvalued in 2026?
Based on GuruFocus' analysis, Coltene Holding AG stock appears to be undervalued.
The current stock price of CHF51.80 is trading 6% below its estimated GF Value™ of CHF55.12.
GuruFocus considers Coltene Holding AG to be Fairly Valued.
Key valuation signals for XSWX:CLTN:
EV-to-EBITDA: 12.83 (near median its 10-year median of 13.07)
GF Value™: CHF55.12 vs. price of CHF51.80 (6% below fair value)
Industry Position: 9.4% below the Medical Devices & Instruments median (#220 of 510)
No single metric tells the full story. See the XSWX:CLTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coltene Holding AG is a manufacturer and distributor of consumables and small devices for dental practices, dental service organisations (DSOs), dental clinics and laboratories, as well as for non-dental niches (e.g., clinics for ophthalmology or podiatry). The Group develops, manufactures, and sells mainly via distribution channels a broad and comprehensive range of disposables, tools, and equipment for dentists and dental laboratories. Geographically, it operates in EMEA, North America, Latin America, and Asia/Oceania, with maximum from North America.
69GF Score
Get the complete analysis for XSWX:CLTN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CLTN has been successfully added to your 
